Related Experiment Videos
Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations
C M Ballantyne1, B Radovancevic, J A Farmer
1Department of Medicine, Methodist Hospital, Houston, Texas.
Insights
Low-dose lovastatin effectively treats hyperlipidemia post-heart transplant. This treatment is well-tolerated and avoids serious side effects like rhabdomyolysis, unlike higher doses.
Area of Science:
- Cardiology
- Pharmacology
- Transplantation Medicine
Background:
- Heart transplantation recipients often develop hyperlipidemia post-surgery.
- Elevated lipid levels increase cardiovascular risk in these vulnerable patients.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose lovastatin monotherapy for hyperlipidemia in heart transplant survivors.
- To compare outcomes of low-dose (≤20 mg/day) versus high-dose lovastatin therapy.
Main Methods:
- Retrospective analysis of lipid profiles in 100 heart transplant patients.
- Assessment of high-dose lovastatin (40-80 mg/day) with other agents in 5 patients.
- Evaluation of low-dose lovastatin (20 mg/day) monotherapy in 15 patients with persistent hyperlipidemia despite dietary intervention.
Main Results:
- High-dose lovastatin (40-80 mg/day) combined with other agents led to rhabdomyolysis in 4/5 patients.
- Low-dose lovastatin (20 mg/day) monotherapy significantly reduced total cholesterol (21%) and LDL cholesterol (31%) in 15 patients.
- Low-dose lovastatin was well-tolerated, with no reported rhabdomyolysis or need for immunosuppression adjustment.
Conclusions:
- Low-dose lovastatin (≤20 mg/day) as monotherapy is a safe and effective treatment for hyperlipidemia after heart transplantation.
- Combination therapy with gemfibrozil or nicotinic acid should be avoided due to adverse events.
- Careful dosing and monotherapy are crucial for managing hyperlipidemia in heart transplant recipients.
Abstract:
Mean plasma lipid values in 100 patients who survived greater than 3 months after heart transplantation increased significantly at 3 months over pretransplantation values: total cholesterol from 168 +/- 7 to 234 +/- 7 mg/dl, low density lipoprotein (LDL) cholesterol from 111 +/- 6 to 148 +/- 6 mg/dl, high density lipoprotein (HDL) cholesterol from 34 +/- 1 to 47 +/- 1 mg/dl and triglycerides from 107 +/- 6 to 195 +/- 10 mg/dl. There were no significant increases after this time. The LDL cholesterol values reamined greater than or equal to 130 mg/dl in 64% of patients and triglyceride values remained greater than or equal to 200 mg/dl in 41% of patients 6 months after postoperative dietary instructions. Beginning in 1985, select patients whose total cholesterol values remained greater than 300 mg/dl despite 6 months of dietary intervention were treated with lovastatin given alone in a high dose (40 to 80 mg/day) or in combination with another hypolipidemic agent. Four of the five patients so treated developed rhabdomyolysis; two of the four had acute renal failure. Beginning in 1988, a second protocol--lovastatin at 20 mg/day as monotherapy--was used in patients who despite dietary intervention had total cholesterol greater than 240 mg/dl (mean follow-up 13 months). In the 15 patients so treated, mean total cholesterol decreased from 299 +/- 10 mg/dl before treatment with lovastatin to 235 +/- 9 mg/dl during treatment (21% reduction, p less than 0.001) and mean LDL cholesterol was reduced from a baseline value of 190 +/- 10 to 132 +/- 12 mg/dl during treatment (31% reduction, p less than 0.001). In this study, lovastatin at a dose of less than or equal to 20 mg/day as monotherapy was a well tolerated, effective treatment for hyperlipidemia after heart transplantation. It did not result in rhabdomyolysis and required no alteration in immunosuppressive therapy. However, the dose should not exceed 20 mg/day and combination therapy with either gemfibrozil or nicotinic acid should be avoided, even if the target LDL cholesterol value is not reached.